Precision BioSciences Profit Margin 2018-2021 | DTIL

Current and historical gross margin, operating margin and net profit margin for Precision BioSciences (DTIL) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Precision BioSciences net profit margin as of September 30, 2021 is -26.91%.
Precision BioSciences Annual Profit Margins
Precision BioSciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.539B $0.024B
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71